AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3516622
Drug: Fructose (0.325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (0.325 g/kg)
Trial: 3516622
Drug: Glucose (0.325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (0.325 g/kg)
Trial: 31023318
Drug: Perioperative systemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative systemic therapy and CRS‐HIPEC
Trial: 27310943
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for BDII for 12 weeks
Trial: 22033719
Drug: Iterative Reconstruction
RxNorm normalized name: CONSTRICTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iterative Reconstruction (IR) at 275 mAs (15% dose reduction)
Trial: 22033719
Drug: Iterative Reconstruction
RxNorm normalized name: CONSTRICTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iterative Reconstruction (IR) at 225 mAs (30% dose reduction)
Trial: 22033719
Drug: Filtered Back-Projection
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filtered Back-Projection (FBP) at 320 mAs (standard dose)
Trial: 22033719
Drug: Filtered Back-Projection
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filtered Back-Projection (FBP) at 275 mAs (15% dose reduction)
Trial: 22033719
Drug: Filtered Back-Projection
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filtered Back-Projection (FBP) at 225 mAs (30% dose reduction)
Trial: 20148254
Drug: 25‐G Quincke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐G Quincke type spinal needle
Trial: 20148254
Drug: 29‐G Quincke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 29‐G Quincke type spinal needle
Trial: 19338490
Drug: C2 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2 levels in schistosomal group (511 ‐/+ 118 nmol/L)
Trial: 19338490
Drug: C2.5 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2.5 levels in schistosomal group (730 ‐/+ 215 nmol/L)
Trial: 2185452
Drug: Cefadroxil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil (1 gm, single-dose)
Trial: 2185452
Drug: Erythromycin (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (high-dose, 1-day regimen)
Trial: 2185452
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no peritreatment antibiotics)
Trial: 381887
Drug: Daunorubicin 60
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin 60 mg/M2 daily X 3, cytosine arabinoside and thioguanine 100 mg/M2 each every 12 hours until marrow hypoplasia achieved
Trial: 381887
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of daunorubicin 100 mg/M2 on day 1, cytosine arabinoside plus thioguanine 100 mg/M2 every 12 hours for five days
Trial: 381887
Drug: 6-mercaptopurine 100
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine 100 mg/M2 daily
Trial: 381887
Drug: 6-thioguanine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-thioguanine 100 mg/M2 daily
Trial: 381887
Drug: 50 mg/M2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/M2 of both 6-mercaptopurine and 6-thioguanine daily
Trial: 31878810
Drug: hEGH gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hEGH gel (Regen-D 150)
Trial: 24227660
Drug: Canagliflozin 50
RxNorm normalized name: canagliflozin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 50 mg
Trial: 19357528
Drug: Lamotrigine (236+/‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (236+/‐150 mg/day)
Trial: 17855483
Drug: BQ-788 (ETB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-788 (ETB receptor blockade)
Trial: 17855483
Drug: BQ-788 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-788 and BQ-123 (combined ET receptor blockade)
Trial: 17855483
Drug: BQ-123 (ETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-123 (ETA receptor blockade)
Trial: 9583767
Drug: Placebo analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo analgesia after buprenorphine treatment
Trial: 9583767
Drug: Placebo respiratory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo respiratory depression after buprenorphine treatment
Trial: 7662835
Drug: Antianginal drug
RxNorm normalized name: ANTIANGINALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antianginal drug
Trial: 2128879
Drug: Daily injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily injections or pulsatile subcutaneous administration of human menopausal gonadotropin (hMG)
Trial: 2128879
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clomiphene citrate and hMG
Trial: 2128879
Drug: Various clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various clinical conditions and types of preparations administered
Trial: 533574
Drug: Oral antipyrine
RxNorm normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipyrine treatment over 4 or 5 weeks in vegetarian Asians and non-vegetarians
Trial: 533574
Drug: Oral antipyrine
RxNorm normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipyrine treatment
Trial: 30148161
Drug: Polyherbal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyherbal formulation (PHF) 750 mg/d in three doses for 90 days
Trial: 24106334
Drug: Clonidine 50
RxNorm normalized name: cloNIDine 500 mcg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 50 µg
Trial: 16265778
Drug: 3-IP (omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-IP (omega-3 fatty acid, 3 g/day)
Trial: 16265778
Drug: 6-IP (omega-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-IP (omega-6 fatty acid, 9 g/day)
Trial: 16265778
Drug: Control (prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (prednisolone 40 mg for 1 week, tapering by 5 mg/week)
Trial: 8634560
Drug: Albendazole 800
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 800 mg twice daily for two weeks
Trial: 2054264
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (300 mg)
Trial: 2054264
Drug: Ferrous gluconate
RxNorm normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous gluconate (600 mg)
Trial: 2054264
Drug: Centrum Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrum Forte (combination tablet)
Trial: 31370976
Drug: Usual dose
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dose of buprenorphine (100%)
Trial: 31370976
Drug: 150% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150% of usual daily dose of buprenorphine
Trial: 31370976
Drug: 200% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200% of usual daily dose of buprenorphine
Trial: 22261849
Drug: Endoscopic CO(2)
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic CO(2) laser resections combined with mitomycin‐C and/or triamcinolone acetonide therapy
Trial: 22261849
Drug: Long‐term oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long‐term oral steroid and immunosuppressive therapy as well as the use of proton pump inhibitors
Trial: 10401941
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg q.i.d. for 3 days)
Trial: 7722951
Drug: Body temperature
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body temperature measurement sites (bladder, oral cavity, rectum, tympanic membrane)
Trial: 2327747
Drug: Piperacillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (4 g every 12 h for four doses) with Tobramycin (2 mg/kg)
Trial: 2327747
Drug: Piperacillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (4 g every 12 h for four doses) with Netilmicin (2 mg/kg)
Trial: 2327747
Drug: Piperacillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (4 g single dose)
Trial: 31362773
Drug: Low-carbohydrate/high-protein (LC/HP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate/high-protein (LC/HP) dietary intervention (30% total energy as protein, 1.6 g/kg per day, carbohydrate-to-protein ratio < 1.5, fat intake at 30% of total energy)
Trial: 31362773
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dietary intervention, regular daily diets)
Trial: 29937536
Drug: Enteric tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric tablets with high-protein meal
Trial: 29937536
Drug: Non-enteric tablets
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non-enteric tablets
Trial: 29937536
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder capsules
Trial: 29937536
Drug: Kwai garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kwai garlic powder tablets
Trial: 19942722
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (n = 4)
Trial: 10412777
Drug: Short-term intensive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intensive therapy (SIT)
Trial: 10412777
Drug: Long-term intermittent
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term intermittent therapy (LIT)
Trial: 6456668
Drug: Intravenous mezlocillin
RxNorm normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mezlocillin (16 gm/day)
Trial: 26938333
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg taken twice daily (n = 48)
Trial: 26938333
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 100 mg daily (n = 41)
Trial: 21820247
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 75-150 μg/d administration
Trial: 20163267
Drug: Alternative systemic
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative systemic agents to first‐line antimonials
Trial: 20163267
Drug: Enhanced topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced topical paromomycin preparation
Trial: 20163267
Drug: Immunotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy and immunomodulators
Trial: 20163267
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro studies of several drugs
Trial: 28762878
Drug: Pitavastatin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (4 mg daily)
Trial: 20927415
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional treatment with RMGIC)
Trial: 18485043
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine, fluoxetine, and sertraline
Trial: 18485043
Drug: Phosphodiesterase-5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase-5 inhibitors
Trial: 18485043
Drug: Topical anaesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetics
Trial: 18485043
Drug: Tramadol (narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (narcotic analgesic)
Trial: 15747269
Drug: Remifentanil (0.10‐0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.10‐0.25 microg/kg/min) with spinal morphine (4 microg/kg) and clonidine (1 microg/kg)
Trial: 15747269
Drug: Sufentanil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (up to 3.5 microg/kg) with patient-controlled administration of intravenous morphine
Trial: 9747741
Drug: Bisphosphonate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate treatment in patients with severe hypercalcaemia (n=51, all treated except one).
Trial: 9747741
Drug: No bisphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bisphosphonate treatment in patients with severe hypercalcaemia (period 1).
Trial: 8605517
Drug: 3.5‐day dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5‐day dietary multibuffer supplement (PhosFuel)
Trial: 788743
Drug: L-noradrenaline infusion
RxNorm normalized name: L-noradrenaline
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-noradrenaline infusion
Trial: 29055668
Drug: Single isocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single isocaloric liquid meal (L-SM) 600-kcal
Trial: 15099277
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.0-2.5)
Trial: 15099277
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.8-4.2)
Trial: 15099277
Drug: Aspirin 160
RxNorm normalized name: aspirin 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 160 mg d(‐1)
Trial: 15099277
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg d(‐1)
Trial: 15099277
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (Aspirin + Warfarin)
Trial: 9803197
Drug: Antihypertensive drug
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drug therapy (diuretics or beta-adrenergic blockers)
Trial: 30653851
Drug: Spironolactone/Pioglitazone/Metformin (SPIOMET),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone/Pioglitazone/Metformin (SPIOMET), n = 24
Trial: 30653851
Drug: Oral Contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive (OC), n = 27
Trial: 24969566
Drug: 16 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g/day Inulin-type fructans (ITF) for 3 months
Trial: 18025439
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy plus autologous stem-cell transplantation (HDCT)
Trial: 11979994
Drug: Therapy for
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy for unstable coronary artery disease according to European Society of Cardiology guidelines
Trial: 10086546
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 mg every 6 hours for 5 days)
Trial: 1754611
Drug: Bright white-light
RxNorm normalized name: Light White Mineral Oil
DrugBank: Light mineral oil (DB11579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white-light treatment (2,500 lux)
Trial: 1754611
Drug: Dim red-light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red-light treatment (50 lux)
Trial: 7031215
Drug: Three days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three days of nitrofurantoin macrocrystals therapy
Trial: 7031215
Drug: Ten days
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten days of nitrofurantoin macrocrystals therapy
Trial: 6094104
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 to 40 mg/day)
Trial: 6094104
Drug: Hydrochlorothiazide plus
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide plus propranolol (50 mg hydrochlorothiazide plus 80 to 240 mg propranolol/day)
Trial: 29933749
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) alone
Trial: 29933749
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) combined with high-dose aspirin
Trial: 19779037
Drug: 15-microg/kg bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-microg/kg bolus followed by a 2-microg/kg/min infusion
Trial: 19779037
Drug: 30-microg/kg bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-microg/kg bolus followed by a 4-microg/kg/min infusion
Trial: 18822490
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol 4 g daily (Group 1)
Trial: 18822490
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol in equipotential dose (Group 2)
Trial: 18822490
Drug: No paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No paracetamol (Group 3)
Trial: 15677777
Drug: Pioglitazone (monotherapy)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (monotherapy)
Trial: 15677777
Drug: Pioglitazone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone plus sulfonylurea (combination therapy)
Trial: 15677777
Drug: Pioglitazone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone plus metformin (combination therapy)
Trial: 15677777
Drug: Metformin (monotherapy)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (monotherapy)
Trial: 15677777
Drug: Gliclazide (monotherapy)
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (monotherapy)
Trial: 15677777
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus sulfonylurea (combination therapy)
Trial: 15677777
Drug: Gliclazide plus
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide plus metformin (combination therapy)
Trial: 2248328
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine (2% dilution in castor oil)
Trial: 30027388
Drug: Higher ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher ratings of the tobacco treatment care transition
Trial: 30027388
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of cessation medication post-discharge
Trial: 26924303
Drug: 54 mg
RxNorm normalized name: aspirin 454 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 54 mg quercetin
Trial: 21067292
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (control group)
Trial: 21221773
Drug: Exemestane (EXE)
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane (EXE) 25 mg daily for 12 months
Trial: 9971914
Drug: Omeprazole enteric-coated
RxNorm normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole enteric-coated formulation A
Trial: 9971914
Drug: Omeprazole enteric-coated
RxNorm normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole enteric-coated formulation B
Trial: 2288396
Drug: Flunisolide aerosol
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide aerosol (0.5 mg administered by a jet nebulizer twice daily for 2 months)
Trial: 16298736
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine (NAC) at 1200 or 1800 mg/day
Trial: 16298736
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration at 2 l/m for 18 h
Trial: 30080128
Drug: Motivational and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational and reminder text messages sent twice a week for 3 months